Hepatoblastoma incidence in Taiwan: A population-based study

Hung, Giun Yi; Li, Lin; Yu, Ting; Lee, Chih Ying; Yen, Hsiu Ju; Horng, Jiun Lin

doi:10.1016/j.jcma.2017.11.012

Cited by 18 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…44 Moreover, not only are risk factors for childhood HCC 4 very different to HB, 9,12 but also differ from adult population. 4,16 In addition, as Nonetheless, several studies suggested that the temporal increase in incidence of the embryonal tumour HB may be attributable to population-level secular trends in pregnancy characteristics especially low birthweight, 30,36,37,39,40,42 which has been consistently associated with childhood HB. 12,15 Improved survival of preterm infants, who may be more susceptible to HB, 14 was another commonly proposed driver of observed trends.…”

Section: Discussionmentioning

confidence: 99%

“…12,15 Improved survival of preterm infants, who may be more susceptible to HB, 14 was another commonly proposed driver of observed trends. 26,30,37,39,40,42 Other possibilities included genetic disorders such as BWS, 26,29,36,37,39,40 increasing maternal age, 30,36,41 and environmental factors. 26,27,29,30,41 Several studies also suggested that observed trends were at least partially an artefact of a systematic change in diagnostic 26,29,30,34,36,37,41 and/or cancer registration or coding practices over time.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Global trends in incidence rates of childhood liver cancers: A systematic review and meta‐analysis

Dasgupta

Henshaw

Youlden

et al. 2020

Paediatric Perinatal Epid

View full text Add to dashboard Cite

Background Childhood liver cancers are relatively rare, hence inferences on incidence trends over time are limited by lack of precision in most studies. Objective To conduct a systematic review and meta‐analysis of published contemporary trends on childhood liver cancer incidence rates worldwide. Data sources PubMed, EMBASE, CINAHL, Web of Science. Study selection and data extraction English‐language peer‐reviewed articles published from 1 January 2008 to 1 December 2019 that presented quantitative estimates of incidence trends for childhood liver cancer and diagnostic subgroups. Review was conducted per PRISMA guidelines. Two authors independently extracted data and critically assessed studies. Synthesis Random effects meta‐analysis models were used to estimate pooled incidence trends by diagnostic subgroups. Heterogeneity was measured using the Q and I2 statistics and publication bias evaluated using Egger’s test. Results Eighteen studies were included, all based on population‐based cancer registries. Trends were reported on average for 18 years. Overall pooled estimates of the annual percentage change (APC) were 1.4 (95% confidence interval [CI] 0.5, 2.3) for childhood liver cancers, 2.8 (95% CI 1.8, 3.8) for hepatoblastoma and −3.0 (95% CI −11.0, 4.9) for hepatocellular carcinoma. Sub‐group analysis by region indicated increasing trends for childhood liver cancers in North America/Europe/Australia (APC 1.7, 95% CI 0.7, 2.8) whereas corresponding trends were stable in Asia (APC 1.4, 95%CI −0.3, 2.7). Publication bias was not detected for any of these analyses. The I2 statistic indicated that the heterogeneity among included studies was low for combined liver cancers, moderate for hepatoblastoma and high for hepatocellular carcinoma. Conclusions Incidence is increasing for childhood liver cancers and the most commonly diagnosed subgroup hepatoblastoma. Lack of knowledge of the etiology of childhood liver cancers limited the ability to understand the reasons for observed incidence trends. This review highlighted the need for ongoing monitoring of incidence trends and etiological studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Global trends in incidence rates of childhood liver cancers: A systematic review and meta‐analysis

Dasgupta

Henshaw

Youlden

et al. 2020

Paediatric Perinatal Epid

View full text Add to dashboard Cite

show abstract

“…Hepatoblastoma is the third most commonly diagnosed intra-abdominal solid tumor [1]. It is also the most common primary hepatic malignancy in children [2].…”

Section: Introductionmentioning

confidence: 99%

Diagnosis and Treatment of Hepatoblastoma: An Update

Zhu¹,

Dong²,

Chen³

et al. 2021

Liver Pathology

View full text Add to dashboard Cite

Hepatoblastoma is a rare but the most common solid tumor in children. The incidence is gradually increasing. The international collaboration among four centers in the world has greatly improved the prognosis of hepatoblastoma. They formed the Children's Hepatic Tumor International Collaboration (CHIC) to standardize the staging system (2017 PRETEXT system) and the risk factors for tumor stratification. Multimodal therapy has become the standard for the management of hepatoblastoma, including surgical resection, liver transplantation, chemotherapy, and so on. Surgery is the primary treatment of early stage hepatoblastoma. Threedimensional reconstruction is helpful for preoperative evaluation of large tumors, assisting extended hepatectomy for patients in PRETEXT III or IV. Neoadjuvant therapy is useful for reducing the tumor volume and increasing the resectability. Primary liver transplantation is recommended for advanced hepatoblastoma. The lungs are the most common metastatic organ, the treatment of which is critical for the patient's long-term survival. We reviewed the recent progress in the diagnosis and treatment of hepatoblastoma.

show abstract

“…Hepatoblastoma is tshe most common childhood liver malignancy, and has a prevalence of 1 per 1,000,000 population [1,2]. The incidence of hepatoblastoma has increased in the past two decades, and this upward trend has been correlated with an increasing survival rate among premature and low-birth-weight infants [3]. Hepatoblastoma usually affects children younger than 3 years, and presents as a large abdominal mass.…”

Section: Introductionmentioning

confidence: 99%

Outcomes of children with hepatoblastoma who underwent liver resection at a tertiary hospital in China: a retrospective analysis

et al. 2020

BMC Pediatr

View full text Add to dashboard Cite

Background: To report the outcomes of hepatoblastoma resected in our institution. Methods: We diagnosed 135 children with hepatoblastoma at our institution between January 2010 and December 2017. Patients who underwent liver resection were included for analysis. However, patients who abandoned treatment after diagnosis were excluded from analysis, but their clinical characteristics were provided in the supplementary material. Results: Forty-two patients abandoned treatment, whereas 93 patients underwent liver resection and were included for statistical analysis. Thirty-six, 23, 3, and 31 patients had PRETEXT stages II, III, IV, and unspecified tumours, respectively. Seven patients had ruptured tumour; 9 had lung metastasis (one patient had portal vein thrombosis concurrently). Sixteen patients underwent primary liver resection; 22, 25, and 30 patients received cisplatin-based neoadjuvant chemotherapy and delayed surgery, preoperative transarterial chemoembolization (TACE) and delayed surgery, and a combination of cisplatin-based neoadjuvant chemotherapy, TACE, and delayed surgery, respectively. Forty patients had both PRETEXT and POST-TEXT information available for analysis. Twelve patients were down-staged after preoperative treatment, including 2, 8, and 2 patients from stages IV to III, III to II, and II to I, respectively. Ten patients with unspecified PRETEXT stage were confirmed to have POST-TEXT stages II (n = 8) and I (n = 2) tumours. Seven tumours were associated with positive surgical margins, and 12 patients had microvascular involvement. During a median follow-up period of 30.5 months, 84 patients survived without relapse, 9 experienced tumour recurrence, and 4 died. The 2-year event-free survival (EFS) and overall survival (OS) rates were 89.4 ± 3.4%, and 95.2 ± 2.4%, respectively; they were significantly better among patients without metastasis (no metastasis vs metastasis: EFS, 93.5 ± 3.7% vs 46.7 ± 19.0%, adjusted p = 0.002. OS, 97.6 ± 2.4% vs 61.0 ± 18.1%, adjusted p = 0.005), and similar among patients treated with different preoperative strategies (chemotherapy only vs TACE only vs Both: EFS, 94.7 ± 5.1% vs 91.7 ± 5.6% vs 85.6 ± 6.7%, p = 0.542. OS, 94.1 ± 5.7% vs 95.7 ± 4.3% vs 96.7 ± 3.3%, p = 0.845).

show abstract

Hepatoblastoma incidence in Taiwan: A population-based study

Cited by 18 publications

References 31 publications

Global trends in incidence rates of childhood liver cancers: A systematic review and meta‐analysis

Global trends in incidence rates of childhood liver cancers: A systematic review and meta‐analysis

Diagnosis and Treatment of Hepatoblastoma: An Update

Outcomes of children with hepatoblastoma who underwent liver resection at a tertiary hospital in China: a retrospective analysis

Contact Info

Product

Resources

About